Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 12/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | CCND1 | P24385 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19526836 | 0.84 | HTR7 (0.57) | HTR7MCL1HTR2AHTR2CCDK4 | |
| SCHEMBL91358 | 0.82 | HTR2A (0.51) | HTR7RENMCL1HTR2AHTR2C | |
| SCHEMBL13962823 | 0.81 | MCL1 (0.46) | RENMCL1HTR2AHTR2CGLO1 | |
| SCHEMBL13962828 | 0.81 | MCL1 (0.46) | RENMCL1HTR2AHTR2CGLO1 | |
| SCHEMBL8265371 | 0.81 | MCL1 (0.46) | RENMCL1HTR2AHTR2CGLO1 | |
| SCHEMBL1049671 | 0.81 | HTR7 (0.51) | HTR7MCL1HTR2AHTR2CGLO1 | |
| SCHEMBL14117445 | 0.79 | GLO1 (0.46) | HTR7HTR2AHTR2CGLO1CDK4 | |
| SCHEMBL78479 | 0.78 | HTR7 (0.53) | HTR7RENMCL1HTR2AHTR2C | |
| SCHEMBL2808277 | 0.78 | ALDH1A1 (0.59) | RENMCL1BCL2MTNR1AMTNR1B | |
| SCHEMBL27403010 | 0.78 | HTR2C (0.43) | HTR7RENMCL1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | HTR7 570/4885REN 1/4885MCL1 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.